Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 27(8): 3270-3287, 2023 04.
Article in English | MEDLINE | ID: mdl-37140277

ABSTRACT

OBJECTIVE: ß-Elemene, a sesquiterpene with a broad anti-cancer spectrum, is particularly effective against drug-resistant and complex tumors. It can also be efficient against FLT3-expressed acute myeloid leukemia. This research aims to determine whether ß-Elemene has cytotoxic effects on FLT3 ITD-mutated AML cells. MATERIALS AND METHODS: Cytotoxicity, cell morphology, mRNA analysis with apoptotic markers, and analysis of 43 distinct protein markers related to cell death, survival, and resistance were all performed to elucidate its mechanism. Additionally, in order to understand how ß-Elemene and FLT3 interact, molecular docking, molecular dynamics simulations, and computational ADME investigations were performed. RESULTS: ß-Elemene exhibited cytotoxic activity against FLT3-mutated MV4-11 and FLT3 wild-type THP-1 cells, with an IC50 of around 25 µg/ml. The molecular studies revealed that ß-Elemene inhibited cell proliferation by inducing p53, and the involvement of p21, p27, HTRA, and HSPs were also demonstrated. The interactive inhibition in proliferation was confirmed via molecular docking and dynamics analyses. ß-Elemene occupied the FLT3 enzymatic pocket with good stability at the FLT3 active site. CONCLUSIONS: We concluded from our observations that ß-Elemene causes cell death in ITD mutant AML cells, together with the effects of stress factors and inhibiting cell division.


Subject(s)
Antineoplastic Agents , Leukemia, Myeloid, Acute , Sesquiterpenes , Humans , Molecular Docking Simulation , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis , Sesquiterpenes/pharmacology , Sesquiterpenes/therapeutic use , Cell Proliferation , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/pathology , fms-Like Tyrosine Kinase 3/genetics , fms-Like Tyrosine Kinase 3/pharmacology , fms-Like Tyrosine Kinase 3/therapeutic use , Cell Line, Tumor , Mutation
2.
Eur Rev Med Pharmacol Sci ; 27(7): 3150-3158, 2023 04.
Article in English | MEDLINE | ID: mdl-37070918

ABSTRACT

OBJECTIVE: The study aimed to evaluate the Withaferin-A against the drug target α-amylase, revealing its plausible mode of action and molecular-level interactions essential for this specific target inhibitory potential computational approach. MATERIALS AND METHODS: In this scenario, we used computational methods, including docking, molecular dynamics simulation, and model-building simulations, to elucidate the atomic-level details responsible for the inhibitory potential of Withaferin-A derived from W. somnifera. The studio visualizer software was used for the visualization of ligands, structures of the receptor, bond length, and rendering of the image. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics of phytochemicals were investigated. Crystal structure of protein receptors and ligands were generated. Semi-flexible docking was done using Autodock software. Docking was performed using the Lamarckian Genetic Algorithm (LGA). Molecular descriptors were evaluated, and the pharmacological properties of the phytochemicals were explored. Molecular dynamic simulations were analyzed at the atomic level. All the simulations were conducted under the same temperature, pressure, and volume circumstances over the simulated time scale. RESULTS: Withaferin-A has shown a strong binding affinity towards α-amylase as demonstrated with -9.79 Kcal/mol with 66.61 estimated nanomolecular IC50 value for plausible anti-obesity activity. Molecular-level relationships and knowledge obtained from this study indicate solid interactions with TYR59, ASP197, and HIS299 residues which are of high importance for future works related to computational screening of target-specific α-amylase inhibitors. The results from the analysis have revealed potential molecular-level interactions useful for further designing/discovering novel α-amylase inhibitors. CONCLUSIONS: The framework of the studied phytochemicals enables the rapid development of subsequent modifications that could result in more lead-like compounds with better inhibitory efficacy and selectivity for α-amylase.


Subject(s)
Molecular Dynamics Simulation , alpha-Amylases , Molecular Docking Simulation , alpha-Amylases/metabolism
3.
Eur Rev Med Pharmacol Sci ; 26(22): 8534-8538, 2022 11.
Article in English | MEDLINE | ID: mdl-36459034

ABSTRACT

INTRODUCTION: The limitations imposed by the blood-brain barrier (BBB) on the sufficient accumulation of antiepileptic drugs (AEDs) in the epileptogenic focus is considered the major cause of the high percentage of morbidity and mortality cases among epilepsy patients. This study aimed at examining the potential effect of insulin on the anticonvulsant action of phenytoin (PHT) in the mouse maximal electroshock-induced seizure model. SUBJECTS AND METHODS: PHT was administered orally in single doses either alone or in combination with insulin given as single intraperitoneal injections. To assess the anticonvulsant activity of PHT, the ED50 values were calculated. The current strength (CS50) threshold for insulin was also estimated. The animals were sacrificed, and the brains were removed to measure their PHT concentrations in the brain. RESULTS: It has been demonstrated that insulin (in all used doses) has no effect on the CS50 but can cause a significant increase in concentrations of PHT in the brain and potentiate the antiepileptic efficiency of this drug in electroshock-induced models of epilepsy in mice. CONCLUSIONS: The combination of insulin with PHT may be of great importance for developing new treatment possibilities following further investigations with other animal models of epilepsy and preclinical studies. Further research is also needed to explore the concentrations of PHT in the brain and the anticonvulsant activity of this drug against maximal electroshock seizures in diabetic mice.


Subject(s)
Diabetes Mellitus, Experimental , Insulin , Animals , Mice , Phenytoin/pharmacology , Electroshock , Anticonvulsants/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Seizures/drug therapy , Seizures/etiology , Disease Models, Animal
4.
Eur Rev Med Pharmacol Sci ; 26(15): 5367-5371, 2022 08.
Article in English | MEDLINE | ID: mdl-35993630

ABSTRACT

OBJECTIVE: Infectious bronchitis virus (IBV), for which no effective drugs are available, is among the most important causes of economic loss within the poultry industry. Apigenin is a flavonoid that can be isolated from plants. Apigenin has low toxicity with anti-viral activity. However, the effects of apigenin against IBV remain unclear. MATERIALS AND METHODS: Thus, here we investigate the anti-viral effect of apigenin on IBV using 10 day-old embryonated eggs by determining the virus titer by embryo infective doses50 (EID50/mL) and determining IBV genomes copy number (per µL) of allantoic fluid. RESULTS: We found that apigenin protected embryonated eggs from IBV. Additionally, apigenin reduced the log titer of the IBV with a significant correlation of up to 9.4 times at 2 µg/egg. Also, apigenin appears to significantly reduce IBV genomes copy number (per µL) in the allantoic fluid. CONCLUSIONS: Apigenin may be a promising approach for the treatment of IBV, since it protects embryonated eggs from IBV in ovo and suppresses viral replication.


Subject(s)
Infectious bronchitis virus , Poultry Diseases , Animals , Apigenin/pharmacology , Viral Load , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL